Stem cell transplantation is nearly available for clinical application in the treatment of ischaemic heart disease (IHD), where it may be joined traditional methods (intervention and surgery). The angiogenic ability of seed cells is essential for this applicability. The aim of this study was to reveal the presence of CD34⁺ angiogenic stem cells in human decidua at the first trimester and to use their strong angiogenic capacity in the treatment of IHD. In vitro, human decidual CD34⁺ (dCD34⁺) cells from the first trimester have strong proliferation and clonality abilities. After ruling out the possibility that they were vascular endothelial cells and mesenchymal stem cells (MSCs), dCD34⁺ cells were found to be able to form tube structures after differentiation. Their angiogenic capacity was obviously superior to that of bone marrow mesenchymal stem cells (BMSCs). At the same time, these cells had immunogenicity similar to that of BMSCs. Following induction of myocardial infarction (MI) in adult rats, infarct size decreased and cardiac function was significantly enhanced after dCD34⁺ cell transplantation. The survival rate of cells increased, and more neovasculature was found following dCD34⁺ cell transplantation. Therefore, this study confirms the existence of CD34⁺ stem cells with strong angiogenic ability in human decidua from the first trimester, which can provide a new option for cell‐based therapies for ischaemic diseases, especially IHD.

中文翻译：

---

人类早孕蜕膜中存在CD34 +血管生成干细胞的证据及其对缺血性心脏病的治疗方法。

干细胞移植在缺血性心脏病（IHD）的治疗中几乎可以临床应用，可以与传统方法（干预和手术）结合使用。种子细胞的血管生成能力对于这种适用性至关重要。这项研究的目的是揭示人早孕蜕膜中CD34 ⁺血管生成干细胞的存在，并利用其强大的血管生成能力治疗IHD。在体外，早孕期的人蜕膜CD34 ⁺（dCD34 ⁺）细胞具有很强的增殖能力和克隆能力。在排除了它们是血管内皮细胞和间充质干细胞（MSC）的可能性后，dCD34 ⁺发现细胞在分化后能够形成管结构。它们的血管生成能力明显优于骨髓间充质干细胞（BMSCs）。同时，这些细胞具有与BMSC相似的免疫原性。在成年大鼠诱发心肌梗塞（MI）后，dCD34 ⁺细胞移植后，梗塞面积减少，心脏功能明显增强。dCD34 ⁺细胞移植后，细胞的存活率增加，并且发现了更多的新脉管系统。因此，这项研究证实了CD34 ⁺的存在 从头三个月开始在人蜕膜中具有强大血管生成能力的干细胞，可以为缺血性疾病（尤其是IHD）的基于细胞的疗法提供新的选择。